Xie Yike, Chen Zhongjian, Su Rui, Li Ye, Qi Jianping, Wu Wei, Lu Yi
Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Shanghai Dermatology Hospital, Shanghai 200443, China.
Curr Drug Deliv. 2017;14(4):483-491. doi: 10.2174/1567201813666160902152122.
Ursodeoxycholic acid, usually used to dissolve cholesterol gallstones in clinic, is a typical hydrophobic drug with poor oral bioavailability due to dissolution rate-limited performance. The objective of this study was to increase the dissolution of ursodeoxycholic acid by amorphous nanosuspensions.
Nanoprecipitation based on acid-base neutralization was used to prepare the nanosuspensions with central composite design to optimize the formula. The nanosuspensions were characterized by particle size, morphology, crystallology and dissolution.
The ursodeoxycholic acid nanosuspensions showed mean particle size around 380 nm with polydispersion index value about 0.25. Scanning electron microscope observed high coverage of HPMC-E50 onto the surface of the nanosuspensions. Differential scanning calorimetry and powder X-ray diffractometry revealed amorphous structure of the ursodeoxycholic acid nanosuspensions. A significant increase of dissolution in acidic media was achieved by the amorphous nanosuspensions compared with the physical mixture.
It can be predicted that the amorphous nanosuspensions show great potential in improving the oral bioavailability of ursodeoxycholic acid.
熊去氧胆酸在临床上常用于溶解胆固醇结石,它是一种典型的疏水性药物,由于溶解速率受限,口服生物利用度较差。本研究的目的是通过无定形纳米混悬液提高熊去氧胆酸的溶出度。
采用基于酸碱中和的纳米沉淀法制备纳米混悬液,并采用中心复合设计优化处方。通过粒径、形态、晶体学和溶出度对纳米混悬液进行表征。
熊去氧胆酸纳米混悬液的平均粒径约为380nm,多分散指数约为0.25。扫描电子显微镜观察到羟丙甲纤维素E50在纳米混悬液表面的高覆盖率。差示扫描量热法和粉末X射线衍射法显示熊去氧胆酸纳米混悬液为无定形结构。与物理混合物相比,无定形纳米混悬液在酸性介质中的溶出度显著提高。
可以预测,无定形纳米混悬液在提高熊去氧胆酸口服生物利用度方面具有巨大潜力。